Safety and Tolerability of Bemdaneprocel in People with Parkinson’s Disease: Results up to 24 Months from a Phase 1 Study
Safety and Tolerability of Bemdaneprocel in People with Parkinson’s Disease: Results up to 24 Months from a Phase 1 Study
Dr. Harini Sarva shares promising safety findings for a natural cell therapy that could offer a new means for delivering dopamine in treating motor symptoms of Parkinson's disease. This highlighted research was presented during the 2024 International Congress of Parkinson’s Disease and Movement Disorders (mdscongress.org). Authors: H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (New York, USA). Funded in part by BlueRock Therapeutics LP. Read the full abstract at mdsabstracts.org.
